Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors
Neuro-Oncology Practice · 26.12.2025 · 12 (6) · 1092-1098
DOI: 10.1093/nop/npaf060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 07.06.2025. Verfasst von Paul Phan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Departmental resources.
Abstract (Originalsprache)
Background
Mebendazole (MBZ) is an anti-helminthic that has shown antitumor activity in mice with gliomas and subsequently in medulloblastoma models. Safety and tolerability have been demonstrated in adults with brain tumors but not explored in children as a monotherapy. We characterized the safety and maximum tolerated dose of oral MBZ in pediatric patients with refractory or progressive brain tumors and assessed progression-free survival (PFS) as a secondary objective.
Methods
Patients up to 21 years of age with refractory or progressive brain tumors were enrolled at 2 centers in a 3 + 3 design with 3 doses of MBZ (1250, 1875, or 2500 mg/m2/day). MBZ was taken orally 3 times per day and continued until there were signs of toxicity or clinical/radiographic progression. Safety and tolerability were analyzed with descriptive statistics.
Results
There were 17 patients enrolled between 2017 and 2022 with diffuse intrinsic pontine gliomas, high-grade astrocytomas, diffuse midline gliomas, glioblastoma multiform, ependymoma, and nonspecific gliomas. At all 3 dose levels, MBZ was well-tolerated with no dose-limiting toxicities. 121 adverse events (AE) including 69 AEs possibly/probably related to MBZ occurred—the most common being decreased lymphocyte count (n = 6). Six grade 3 (anorexia, dehydration, hypokalemia, increased GGT, blood bilirubin increased, and aspartate aminotransferase increased) and 1 grade 4 (vomiting) were reported. The mean PFS was 7.6 weeks (range of 2 to 24 weeks).
Conclusions
MBZ is safe and tolerable in treating refractory or progressive pediatric brain tumors, with doses up to 2500 mg/m2/day. There was limited evidence of single-agent efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
- Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Cellular and Molecular Medicine Program, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
ORCID-Profile: Eric Raabe, Kenneth J Cohen
Förderung
- Departmental resources
Zitieren
APA
Phan, P., Stapleton, S. L., Riggins, G. J., Koldobskiy, M. A., Raabe, E., & Cohen, K. J. (2025). Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors. Neuro-Oncology Practice, 12(6), 1092-1098. https://doi.org/10.1093/nop/npaf060
Vancouver
Phan P, Stapleton SL, Riggins GJ, Koldobskiy MA, Raabe E, Cohen KJ. Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors. Neuro-Oncology Practice. 2025;12(6):1092-1098. doi:10.1093/nop/npaf060
BibTeX
@article{Phan2025,
author = {Phan, Paul and Stapleton, Stacie L and Riggins, Gregory J and Koldobskiy, Michael A and Raabe, Eric and Cohen, Kenneth J},
title = {Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors},
journal = {Neuro-Oncology Practice},
year = {2025},
volume = {12},
number = {6},
pages = {1092--1098},
doi = {10.1093/nop/npaf060}
}
EUVIMED